United Therapeutics (UTHR), DEKA Report Additional FDA Clearance Related to Unity Subcutaneous Delivery System for Remodulin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
United Therapeutics (UTHR) Misses Q4 EPS by 69c, Revenues Miss
February 26, 2020 6:07 AM ESTUnited Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $1.96, $0.69 worse than the analyst estimate of $2.65. Revenue for the quarter came in at $311.1 million versus the consensus estimate of $357.77 million.
"Following the positive results of the INCREASE study of Tyvaso® (treprostinil) Inhalation Solution in pulmonary hypertension associated with interstitial lung disease (ILD), we're looking forward to submitting a... More
United Therapeutics (UTHR) Reports INCREASE Study of Tyvaso Meets Primary and All Secondary Endpoints
February 24, 2020 6:02 AM ESTUnited Therapeutics Corporation (NASDAQ: UTHR) today announced that preliminary analysis indicates that the INCREASE clinical study of Tyvaso® (treprostinil) Inhalation Solution in patients suffering from World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD) has met its primary efficacy endpoint of demonstrating improvement in six-minute walk distance (6MWD).
Tyvaso increased six-minute walk distance by 21 meters versus placebo (p=0.0043, Hodges-Lehmann estimate) after 16 weeks of treatment. Benefits of Tyvaso were observed across several key subgroups, including etiology of PH-ILD, disease severity, age, gender, baseline hemodynamics, and... More
